BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAB8. A total of 41 filers reported holding BRIDGEBIO PHARMA INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,540,444 | +1.0% | 4,495,000 | +7.2% | 0.00% | – |
| Q1 2024 | $4,494,397 | -11.1% | 4,195,000 | 0.0% | 0.00% | – |
| Q4 2023 | $5,057,073 | +43.3% | 4,195,000 | +13.5% | 0.00% | – |
| Q3 2023 | $3,528,725 | +45.7% | 3,695,000 | +19.4% | 0.00% | – |
| Q2 2023 | $2,422,518 | -11.5% | 3,095,000 | -16.8% | 0.00% | – |
| Q1 2023 | $2,737,920 | +4.8% | 3,720,000 | -36.6% | 0.00% | – |
| Q4 2022 | $2,612,150 | -8.9% | 5,870,000 | +20.5% | 0.00% | – |
| Q3 2022 | $2,867,000 | +8.3% | 4,870,000 | 0.0% | 0.00% | – |
| Q2 2022 | $2,648,000 | +6.8% | 4,870,000 | +12.7% | 0.00% | – |
| Q1 2022 | $2,480,000 | -1.7% | 4,320,000 | +25.4% | 0.00% | – |
| Q4 2021 | $2,522,000 | -46.8% | 3,445,000 | 0.0% | 0.00% | – |
| Q3 2021 | $4,745,000 | +11.5% | 3,445,000 | +32.8% | 0.00% | – |
| Q2 2021 | $4,256,000 | -37.1% | 2,595,000 | -36.8% | 0.00% | – |
| Q1 2021 | $6,770,000 | – | 4,105,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BRAIDWELL LP | 140,838,000 | $142,965,899 | 4.48% |
| Affinity Asset Advisors, LLC | 17,000,000 | $17,256,850 | 1.99% |
| 683 Capital Management, LLC | 23,250,000 | $23,191,875 | 1.75% |
| Weiss Asset Management LP | 42,260,000 | $42,784,504 | 1.62% |
| Graham Capital Management, L.P. | 73,241,000 | $73,856,085 | 1.61% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 28,115,000 | $28,746,703 | 0.69% |
| ARISTEIA CAPITAL, L.L.C. | 26,923,000 | $27,329,774 | 0.60% |
| LINDEN ADVISORS LP | 64,125,000 | $64,640,325 | 0.54% |
| SSI INVESTMENT MANAGEMENT LLC | 4,690,000 | $4,727,520 | 0.36% |
| WOLVERINE ASSET MANAGEMENT LLC | 15,840,000 | $15,982,712 | 0.18% |